ONCT - Oncternal Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

-35.39M

Cash

54.32M

Avg Qtr Burn

-9.767M

Short % of Float

0.51%

Insider Ownership

8.61%

Institutional Own.

17.78%

Qtr Updated

03/31/23

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
ONCT-808 (CAR-T) Details Solid tumor/s, Hematologic malignancies, Cancer	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ONCT-534 Details Cancer, Castration-resistant prostate cancer	IND Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Zilovertamab (Cirmtuzumab) (ROR1) + Ibrutinib Details Blood cancer, Chronic lymphocytic leukemia, Cancer, Mantle cell lymphoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Zilovertamab (Cirmtuzumab) (ROR1) + Paclitaxel Details Cancer, Metastatic breast cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ONCT-216 (TK216) (EWS-FLI1 inhibitor) Details Relapsed/refractory Ewing sarcoma, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Zilovertamab (Cirmtuzumab) (ROR1) + Ibrutinib Details Blood cancer, Cancer, Mantle cell lymphoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.